title: The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial.
abstract: BACKGROUND
  High quality evidence indicates that aspirin is effective in reducing colorectal polyps; and numerous epidemiological studies point towards an ability to prevent colorectal cancer. However the role of Aspirin as an adjuvant agent in patients with established cancers remains to be defined. Recently a nested case-control study within the Nurses Health cohort suggested that the initiation of Aspirin after the diagnosis of colon cancer reduced overall colorectal cancer specific mortality. Although this data is supportive of Aspirin's biological activity in this disease and possible role in adjuvant therapy, it needs to be confirmed in a randomized prospective trial.
  
  
  METHODS
  We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. The primary endpoint of this study is Disease Free Survival and the secondary Endpoint is 5 yr Overall Survival. This study will randomize eligible patients with Dukes C or high risk Dukes B colorectal cancer, after completion of surgery and standard adjuvant chemotherapy (+/- radiation therapy for rectal cancer patients) to 200 mg Aspirin or Placebo for 3 years. Stratification factors include study centre, rectal or colon cancer stage, and type of adjuvant chemotherapy (exposed/not exposed to oxaliplatin). After randomization, patient will be followed up with 3 monthly assessments whilst on study drug and for a total of 5 years. Patients with active peptic ulcer disease, bleeding diathesis or on treatment with aspirin or anti-platelet agents will be excluded from the study.
  
  
  CONCLUSIONS
  This study aims to evaluate Aspirin's role as an adjuvant treatment in colorectal cancer. If indeed found to be beneficial, because aspirin is cheap, accessible and easy to administer, it will positively impact the lives of many individuals in Asia and globally.
  
  
  BACKGROUND
  Clinicaltrials.gov: NCT00565708.
authors.affiliation: INDOX Cancer Research Network, Richard Doll building, University of Oxford OX37LF, UK.
authors.forename: Raghib
authors.initials: R
authors.lastname: Ali
authors.forename: Han-Chong
authors.initials: HC
authors.lastname: Toh
authors.forename: Whay-Kuang
authors.initials: WK
authors.lastname: Chia
mesh_terms: D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002985:Clinical Protocols; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D018401:Sample Size
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D001241:Aspirin